News and Trends 4 Jan 2018 Boehringer Ingelheim Doubles its Venture Fund for Exciting Biotech Boehringer Ingelheim has committed to continue helping young companies grow by doubling the size of its venture fund to €250M, which will allow it to expand its focus. Boehringer Ingelheim is a big pharma hoping to drive the development of new and effective medicines. Today, the company announced that it has more than doubled the size of […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner Santa Claus is not the only busy one in the weeks leading up to Christmas this year, with Boehringer Ingelheim signing collaborations with Autifony and Evox Therapeutics. In the last couple of days, Boehringer Ingelheim has agreed to collaborate with two exciting British biotechs. On Monday, a deal worth up to €627.5M was agreed with CNS disorders specialist, […] December 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […] November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […] September 18, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2017 French Biotech Lures Big Pharma with Fibrosis Treatments This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […] September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2017 Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting […] August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2016 Another Pharma sloughs off Small Molecules to focus on Biologics BI has taken an axe to its small molecule discovery program in order to focus on immuno-oncology in the latest farewell to old-school chemical drugs. Over 90% of the drugs on the market today are small molecules, but the bell has been tolling for these therapies for some time now as biopharma is increasingly focused […] December 5, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Boehringer’s Biosimilar could take a Chunk out of the Cancer Market Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […] November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2016 Boehringer enters the Biosimilar War against Blockbuster Humira Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […] October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 Overseas Deaths in the Clinic come as a Blow to Boehringer Ingelheim Boehringer Ingelheim has swiftly dumped its olmutinib collaboration with Hanmi following news of deaths in South Korean Phase II trials. An investigation by the South Korean Ministry of Food and Drug Safety has linked several deaths to olmutinib, a lung cancer drug launched by Hanmi. Sound familiar? Boehringer Ingelheim just signed a deal to acquire the […] October 10, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Boehringer buys a €210M ticket to Virus-based Immuno-Oncology Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […] September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email